Long-term outcomes of totally implantable venous access devices

Wang, Yi-Chia; Lin, Pei-Lin; Chou, Wei-Han; Lin, Chih-Peng; Huang, Chi‐Hsiang

doi:10.1007/s00520-017-3592-0

Cited by 25 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall postoperative complication rate in this study was 4.48% (3/67), which was lower than that in most other studies [12, 24]. Catheter-related infections were found in 1 case 5 weeks after surgery.…”

Section: Discussioncontrasting

confidence: 63%

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Qin

Zheng

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

BackgroundTo evaluate the feasibility and safety of ultrasound-guided totally implantable venous access port (TIVAP) implantation via the right innominate vein in patients with breast cancer.MethodsSixty-seven breast cancer patients underwent ultrasound-guided implantation of TIVAPs via the right innominate vein for administration of chemotherapy. Clinical data including technical success, success rate for the first attempt, periprocedural, and postoperative complications were recorded and retrospectively studied.ResultsAll patients underwent successful surgery. The success rate of the first attempt was 95.52% (64/67). The operation time was 28 to 45 min, with an average of 36 ± 6 min. Periprocedural complications included artery punctures in 1 (1.50%, 1/67) patient. Prior to this study, the mean TIVAP time was 257 ± 3 days (range 41 to 705 days). The rate of postoperative complications was 4.48% (3/67), including catheter-related infections in 1 case and fibrin sheath formation in 2 cases. Up to the present study, three people had unplanned port withdrawal due to complications, and the TIVAPs for 25 patients were still in normal use.ConclusionsThe success rate of ultrasound-guided TIVAPs via the right innominate vein is high with low complications, thus safe and feasible. This technique can provide a new option for chemotherapy of breast cancer patients.

show abstract

Section: Discussioncontrasting

confidence: 63%

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Qin

Zheng

et al. 2019

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Retrospective studies of Wang et al [5] involving 235 cases reported that the mean age of cases was 58.2 years, 62.5% being female. Totally implantable venous port catheter was applied most commonly in breast, lung and colorectal cancer cases.…”

Section: Discussionmentioning

confidence: 99%

“…They concluded that there was no significant difference in infection rate when antibiotic prophylaxis was used. Similarly, Wang et al [5] reported that the principal reasons for premature catheter removal were port-associated blood stream infection and a suboptimal tip position. The port-associated blood stream infection was more prevalent in hematologic and upper gastrointestinal cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…TIVPCs have important advantages such as low risk of infection, long-term ease of use, no restriction on daily activities and being able to continue therapy at home. [4,5] In our clinic, TIVPC insertion has been gradually increasing in last 12 years. While the number of procedures was approximately 100 cases/year during the preliminary years, it increased to 300 cases/year in recent years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Experience in totally implantable venous port catheter: Analysis of 3,000 patients in 12 years

Yanık

Karamustafaoğlu

Karataş

et al. 2018

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

“…The most common TIVAD-related complications in patients with cystic fibrosis include occlusion, infection, leakage, pain or discomfort, venous thrombosis, stenosis, and port extrusion [ 7 , 8 ]. In patients with cancer, common TIVAD complications include infection, sepsis, thrombosis, skin dehiscence, and pain [ 6 , 9 , 10 ]. While some overlap exists, the complication profile for TIVAD use for LSDs is unique.…”

Section: Discussionmentioning

confidence: 99%

Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders

Hendriksz

Harmatz

Giugliani

et al. 2018

Molecular Genetics and Metabolism Reports

View full text Add to dashboard Cite

Totally implantable vascular access devices (TIVADs) are commonly used in conjunction with enzyme replacement therapy (ERT) for lysosomal storage disorders (LSDs). This case series describes potential complications associated with long-term TIVAD use, such as compromise of skin integrity, infection, or port failures. Best practices and skilled specialists are essential for minimizing complications from long-term TIVAD use for ERT.

show abstract

Long-term outcomes of totally implantable venous access devices

Cited by 25 publications

References 26 publications

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Ultrasound-guided totally implantable venous access ports via the right innominate vein: a new approach for patients with breast cancer

Experience in totally implantable venous port catheter: Analysis of 3,000 patients in 12 years

Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders

Contact Info

Product

Resources

About